Bioporto Diagnostics is exhibiting at the 24th Annual Congress of the European Society of Intensive Care Medicine.
Over 5,400 participants will gather to learn the latest intensive care medicine findings in a growing event with more than 60 exhibitors, 20 satellite symposia and over 1,300 submitted abstracts.
BioPorto Diagnostic will be promoting The NGAL Test™, a test measuring the emerging kidney biomarker; NGAL. The NGAL Test™ is CE IVD registered for diagnostic use in Europe and Canada, and available for research use only in the United States.The NGAL Test™ is currently pending FDA clearance for diagnostics use in the United States.
What is NGAL?
NGAL is a biomarker for diagnosing acute kidney injury (AKI). The biomarker has been recognised by the market as a new way to identify patients at risk of developing potentially severe acute kidney injury (AKI).
For further information please visit: http://www.esicm.org/Data/ModuleGestionDeContenu/PagesGenerees/07-congresses/0A-annual-congress/105.asp